NOTICE: Thank you for visiting our site. Your experience is important to us. We're upgrading our system to better serve you. During this time, purchases and member logins will be unavailable. Full functionality will be restored by Monday, 29 July.
ISPE President and CEO Thomas Hartman provides insights on how AI may impact the biotech industry in 2024. Thomas observes that the meteoric rise of AI took every industry by surprise in 2023. In 2024, he notes, “companies will have more time to take a step back and properly evaluate their technology and resources.”
Labiotech.eu provides information, analyses, and insights on the biotech industry for European audiences.